W1121 Long-Term Benefits of Dexlansoprazole MR on Quality of Life and Symptom Severity Among Gastroesophageal Reflux Disease (GERD) Patients

Abstract

G A A b st ra ct s FSSG score following treatment. Results: No significant differences were seen between groups in subject background or baseline FSSG scores. Four weeks treatment with rikkunshito combined with RPZ decreased FSSG scales from 15.8 ± 5.0 to 10.4 ± 6.2 (p<0.001) similar to the treatment with a double dose of RPZ (from 15.7 ± 7.8 to 11.4 ± 9.0, p<0.001). Significant efficacy was also observed for each FSSG subscale in both treatment groups. Therapeutic improvement was achieved in 10 (33.3%) patients receiving rikkunshito and 14 (40%) patients treated with RPZ alone. In contrast, the proportion of subjects worsening after treatment was higher in patients treated with RPZ alone (27.2%) than in patients receiving rikkunshito (13.3%). The proportions of subjects experiencing therapeutic improvement were 70% receiving rikkunshito and 42.1% treated with RPZ alone in subset analyses for BMI≤22 groups. However, in terms of age and gender, there was no difference between both groups. Conclusions: Rikkunshito combined with a standard dose of RPZ demonstrated a substantial effect on the symptoms of refractory NERD patients similar to a double dose regimen of RPZ. In particular for slender NERD patients, a combination with rikkunshito may be a useful therapeutic modality.